Akebia's Vafseo Trial Halted Early for Superior Safety Outcomes
AKBA sits 40% above its 52-week low of $0.823.
Summary
Akebia Therapeutics announced that its VOICE trial for Vafseo was stopped early due to overwhelming statistical evidence of improved safety outcomes. An interim analysis showed a statistically significant and clinically meaningful reduction in the primary composite endpoint of all-cause mortality and hospitalization, driven by a decrease in hospitalizations, for patients treated with Vafseo compared to an ESA. This positive data, following a recent patent grant and post-hoc analysis publication for Vafseo, significantly strengthens the drug's profile and competitive position in the anemia due to CKD market. The companies plan to present the full data at an upcoming scientific meeting.
At the time of this announcement, AKBA was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.8M. The 52-week trading range was $0.82 to $4.08. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.